Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results

LAVAL, Quebec, May 2, 2013 /PRNewswire/ --

  •  2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year
  •  2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year
    •  Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet
    •  Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet
  •  2013 First Quarter GAAP EPS Loss of $0.09; Cash EPS $1.30, an increase of 43% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 First Quarter GAAP Operating Cash Flow $255 million; Adjusted Operating Cash Flow $345 million; an increase of 35% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 Guidance for Cash EPS raised to $5.55 to $5.85 despite entry of Zovirax generic ointment

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces first quarter financial results for 2013.

"Despite a slow January due to the integration of the Valeant and Medicis sales organizations, we delivered another solid quarter of strong growth in Cash EPS and adjusted cash flow to our shareholders," stated J. Michael Pearson, chairman and chief executive officer.  "We were particularly pleased with the strong organic growth of our emerging market segment, which was primarily driven by Poland, Russia, Brazil, South East Asia, and South Africa, as well as the continued growth in many of our promoted brands."

Revenue

Valeant's total revenues were $1.068 billion, up 25% compared to the first quarter of 2012, and product revenues were $1.039 billion, up 38% versus the year-ago quarter. 

Valeant's U.S. Promoted product sales increased 91% to $479 million led by strong growth in key brands such as Acanya, CeraVe, Arestin, Dysport, Restylane, Perlane and AcneFree.  On a same store sales organic growth basis, U.S. Promoted business increased 6% despite increased generic competition in BenzaClin. Excluding the impact on BenzaClin sales, same store sales organic growth for this portfolio would have been 12% for the first quarter of 2013.  Pro forma organic growth was flat as compared to the prior year due to the harmonization of wholesaler contracts between Valeant and Medicis.  The wholesaler inventory levels of the Medicis dermatology portfolio were reduced from more than two months to approximately one month.  Excluding this impact, pro forma organic growth was 7% in the first quarter of 2013.

Our U.S. Neurology and Other business delivered an EBITA contribution that was flat as compared to the prior year based on the stabilization of Wellbutrin XL and growth in several orphan drug products.  This improvement was achieved in spite of a decrease in overall sales primarily from a reduction in partnered generic products which are low margin (e.g. diltiazem CD, nifedipine) and the slow launch of fenofibrate. We expect the top line growth in this division to be flat to slightly up for the full year 2013 and growth in EBITA versus 2012.

Our Canadian business reported strong growth in key brands for the quarter, including COLD-FX, CeraVe and our dermatology franchise, which was offset by the continued decline in Cesamet, while our Australian operations continued to perform well.

Finally, our Emerging Markets segment performed extremely well in the first quarter and product sales increased 26% driven by outstanding growth in Poland, Russia, Brazil, South East Asia and South Africa. 

Financial Performance

The Company reported a net loss of $28 million for the first quarter of 2013, or a loss of $0.09 per diluted share.  On a Cash EPS basis, adjusted income was $405 million, or $1.30 per diluted share.  Excluding gains on the divestiture of two dermatology products and a foreign exchange gain related to the acquisition of iNova in the first quarter of 2012, Cash EPS increased 43% over the year-ago quarter.   

GAAP cash flow from operations was $255 million in the first quarter of 2013, and adjusted cash flow from operations was $345 million.

The Company's cost of goods sold (COGS) was $285 million in the first quarter of 2013.  After backing out the fair value adjustment to inventory, amortization expense and other items related to acquisitions, COGS represented 22% of product sales, a decrease of three percentage points as compared to the first quarter of 2012 due to a favorable product mix, global plant consolidations and other initiatives.   

Selling, General and Administrative expenses were $242 million in the first quarter of 2013, or approximately 23% of revenue, which was an increase of 4% over the prior year.  SG&A was unusually high this quarter due to the integration of Medicis, and we expect this ratio to return to historical levels for the remainder of 2013. Research and Development expenses were $24 million in the first quarter of 2013, or approximately 2% of revenue.

2013 Guidance

The Company is updating its previous Cash EPS guidance and is now targeting Cash EPS of $5.55 to $5.85 in 2013, despite a recent entry of Zovirax generic ointment, up from prior guidance of $5.45 to $5.75. Total revenue in the range of $4.4 to $4.8 billion and adjusted cash flow from operations of $1.5 to $1.75 billion is reaffirmed.  

Conference Call and Webcast Information

The Company will host a conference call and a live Internet webcast along with a slide presentation today at 7:30 a.m. ET (4:30 a.m. PT), May 2, 2013 to discuss its first quarter financial results for 2013. The dial-in number to participate on this call is (877) 876-8393 confirmation code 41820189. International callers should dial (973) 200-3961, confirmation code 41820189. A replay will be available approximately two hours following the conclusion of the conference call through May 9, 2013 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 41820189. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding our expected performance for 2013, including 2013 guidance with respect to Cash EPS, total revenue and adjusted cash flow from operations, and COGS for 2013.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Non-GAAP Information 

To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Financial Tables follow.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

Valeant Pharmaceuticals International, Inc.




 Table 1 

Condensed Consolidated Statements of Income (Loss)





For the Three Months Ended March 31, 2013 and 2012












Three Months Ended



March 31,

(In thousands, except per share data)


2013


2012






Product sales


$  1,038,867


$      750,880

Alliance and royalty


9,258


79,231

Service and other


20,230


25,992

Total revenues


1,068,355


856,103






Cost of goods sold (exclusive of amortization of intangible assets shown separately below)


284,904


224,196

Cost of services


14,951


18,820

Cost of alliances


478


68,820

Selling, general and administrative ("SG&A")


241,899


177,286

Research and development


23,795


22,006

Acquisition-related contingent consideration


(2,185)


9,839

Legal settlements and related fees


4,448


3,155

Restructuring, acquisition-related and other costs


56,884


69,842

Amortization of intangible assets


326,175


200,643



951,349


794,607

Operating Income (loss)


117,006


61,496






Interest expense, net


(153,719)


(100,902)

Loss on extinguishment of debt


(21,379)


(133)

Gain (loss) on investments, net


1,859


2,059

Foreign exchange and other


1,439


24,299






Income (loss) before (recovery) provision for income taxes


(54,794)


(13,181)






Recovery of income taxes 


(27,264)


(260)






Net (loss) income


$     (27,530)


$      (12,921)






Earnings per share:










Basic and Diluted:





Net loss


$         (0.09)


$          (0.04)

Shares used in per share computation


305,763


307,776

 

Valeant Pharmaceuticals International, Inc.




 Table 2 

Reconciliation of GAAP EPS to Cash EPS 


For the Three Months Ended March 31, 2013 and 2012

















Three Months Ended



March 31,

(In thousands, except per share data)


2013


2012






Net (loss) income


$      (27,530)


$      (12,921)






Non-GAAP adjustments(a):





Inventory step-up (b)


43,241


33,031

Alliance product assets & pp&e step-up/down(c)


138


50,721

Stock-based compensation step-up (d)


(280)


10,428

Acquisition-related contingent consideration(e)


(2,185)


9,839

Legal settlements and related fees(f)


4,448


3,155

Restructuring, acquisition-related and other costs(g)


56,884


69,842

Amortization and other non-GAAP charges(h)


336,775


205,203



439,021


382,219

Amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest(i)


9,647


5,750

Loss on extinguishment of debt


21,379


133

Tax(j)


(37,355)


(14,859)

Total adjustments


432,692


373,243






Adjusted net income


$     405,162


$      360,322






GAAP earnings per share - diluted


$          (0.09)


$          (0.04)






Cash earnings per share - diluted


$           1.30


$            1.14






Cash earnings per share excluding one-time items - diluted


$           1.30


$            0.91






Shares used in diluted per share calculation - Cash earnings per share


312,350


316,397











(a) See footnote (a) to Table 2a.





(b) See footnote (b) to Table 2a.





(c) See footnote (d) to Table 2a.





(d) See footnote (e) to Table 2a.





(e) See footnote (f) to Table 2a.





(f) See footnote (g) to Table 2a.





(g) See footnotes (h) (i) Table 2a.





(h) See footnote (c) to Table 2a.





(i) See footnote (j) to Table 2a.





(j) See footnote (k) to Table 2a.





 


Valeant Pharmaceuticals International, Inc.

 Table 2a 


Reconciliation of GAAP EPS to Cash EPS 



For the Three Months Ended March 31, 2013 and 2012











Non-GAAP Adjustments(a)for




Three Months Ended




March 31,


(In thousands, except per share data)


2013


2012








Product sales


$              -


$                -


Alliance and royalty


-


-


Service and other


-


-


Total revenues


-


-








Cost of goods sold (exclusive of amortization of intangible assets shown separately below)


(53,989)

 (b)(c) 

(36,421)

 (b)(c) 

Cost of services


-


-


Cost of alliances


-


(50,958)

 (d) 

Selling, general and administrative ("SG&A")


290

 (e) 

(11,361)

 (e) 

Research and development


-


-


Acquisition-related contingent consideration


2,185

 (f) 

(9,839)

 (f) 

Legal settlements and related fees


(4,448)

 (g) 

(3,155)

 (g) 

Restructuring, acquisition-related and other costs


(56,884)

 (h) 

(69,842)

 (i) 

Amortization of intangible assets


(326,175)


(200,643)




(439,021)


(382,219)


Operating Income (loss)


439,021


382,219








Interest expense, net


9,647

 (j) 

5,750

 (j) 

Loss on extinguishment of debt


21,379


133


Gain (loss) on investments, net


-


-


Foreign exchange and other


-


-








Income (loss) before (recovery) provision for income taxes


470,047


388,102








(Recovery) provision for income taxes 


37,355

 (k) 

14,859

 (k) 







Total Adjustments to Net income 


$     432,692


$      373,243








Earnings per share:












Diluted:






Total Adjustments to Net income


$           1.39


$            1.18


Shares used in per share computation


312,350


316,397














(a) To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. 


Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. 


(b) ASC 805, accounting for business combinations requires an inventory fair value step-up whose total impact for the three months ended March 31, 2013 is $43.2 million primarily relating to the acquisition of Medicis Pharmaceutical Corporation on December 11, 2012.  For the three months ended March 31, 2012 the impact of inventory fair value step-up is $33.0 million primarily relating to the acquisitions of Dermik on December 16, 2011 and iNova on December 21, 2011.


(c) For the three months ended March 31, 2013 and 2012 cost of goods include costs associated with integration related tech transfers, $7.6 million and $1.6 million, respectively.  For the three months ended March 31, 2013 cost of goods includes a BMS fair value inventory adjustment of $2.1 million.


(d) Cost of Alliances represents the divestiture of 5-FU and IDP-111 resulting from the acquisition of Dermik, $50.9 million for the three months ended March 31, 2012. 


(e)  For the three months ended March 31, 2013 and 2012 SG&A primarily includes an insignificant amount and $10.4 million of stock-based compensation, respectively, which reflects the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail and the acceleration of certain equity instruments.


(f) Net expenses from the changes in acquisition related contingent consideration for the three months ended March 31, 2013 and 2012 of $2.2 million and $9.8 million, respectively.


(g)  For the three months ended March 31, 2013 and 2012 legal settlement costs of $4.4 million and $3.2 million, respectively, relate to settlements and associated legal fees of patent-related litigations.


(h) Restructuring, acquisition-related and other costs of $56.9 million primarily represents costs related to the acquisition of Medicis and other Valeant restructuring and integration initiatives.   These include $24.5 million related to integration consulting, duplicative labor, transition services, and other, $15.8 million related to employee severance costs, $7.9 million related to acquisition costs, $4.3 million related to facility closure costs, $2.7 million related to other, and $1.7 million related to non-personnel manufacturing integration costs.


(i) Restructuring, acquisition-related and other costs of $69.8 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and the acquisitions of Afexa, iNova, Dermik, Sanitas, Ortho Dermatologics, PharmaSwiss SA, Probiotica and Eyetech.  These costs include $20.2 million related to facility closure costs, $20.5 million related to contract cancellation fees, consulting, legal and other costs, $19.8 million related to severance, $7.5 million related to acquisition costs, and $1.8 million related to manufacturing integration.


(j) Non cash interest expense associated with amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest totals for the three months ended March 31, 2013 and 2012 of $9.6 million and $5.8 million, respectively.


(k) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset.


 


Valeant Pharmaceuticals International, Inc.

 Table 3 

Statement of Revenues - by Segment


For the Three Months Ended March 31, 2013 and 2012

(In thousands)

























 Three Months Ended 


March 31,

Revenues(a)(b)


2013
GAAP



2012
GAAP


%   Change


2013 currency impact


2013 excluding currency impact
 non-GAAP


%   Change

    U.S. Promoted

$      482,636


$     327,955


47%


$            -


$     482,636


47%

    U.S. Neurology & Other

159,966


158,364


1%


-


159,966


1%

    Canada/Australia

128,542


132,569


-3%


1,384


129,926


-2%

Developed Markets

771,144


618,888


25%


1,384


772,528


25%

    Emerging Markets-Central/Eastern Europe

186,166


144,398


29%


(300)


185,866


29%

    Emerging Markets-Latin America

81,709


70,874


15%


3,160


84,869


20%

    Emerging Markets-Southeast Asia/Africa

29,336


21,943


34%


1,706


31,042


41%

Emerging Markets

297,211


237,215


25%


4,566


301,777


27%

Total Revenues

$   1,068,355


$     856,103


25%


$      5,950


$  1,074,305


25%













(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. 


(b) See footnote (a) to Table 2a.

 

Valeant Pharmaceuticals International, Inc.




Table 4

Reconciliation of GAAP Cost of Goods Sold to Non-GAAP Cost of Goods Sold - by Segment



For the Three Months Ended March 31, 2013





(In thousands)























4.1

Cost of goods sold (a)
























 Three Months Ended 




March 31,




2013
as reported
GAAP


%
of product sales


2013
 fair value step-up adjustment to inventory and Other non-GAAP    (b)


2013 excluding fair value step-up adjustment to inventory and Other
non-GAAP


%
of product sales


Developed Markets


$  159,412


21%


$       46,904


$     112,508


15%


Emerging Markets


125,492


44%


7,085


118,407


41%
















$  284,904


27%


$       53,989


$     230,915


22%


























(a) See footnote (a) to Table 2a.














(b) Developed Markets includes $41.0 million of fair value step-up adjustment to inventory and $6.1 million of integration related tech transfer costs offset by PP&E step down of $0.2 million.  Emerging Markets includes $2.2 million of fair value step up adjustment to inventory, $1.5M of integration related tech transfer costs, $2.1 million BMS fair value inventory adjustment and $1.3 million of PP&E step up and other.

 



Valeant Pharmaceuticals International, Inc.




Table 5



Consolidated Balance Sheet and Other Data







(In thousands)









As of


As of






March 31,


December 31,




5.1

Cash

2013


2012













Cash and cash equivalents

$      413,736


$      916,091





Marketable securities

10,092


4,410





Total cash and marketable securities

$      423,828


$      920,501





















Debt
















New Term Loan A Facility

$   1,926,577


$   2,083,462





New Term Loan B Facility

1,265,726


1,275,167





New Incremental Term Loan B Facility

973,765


973,988





Senior Notes

6,450,001


6,448,317





Convertible Notes

209


233,793





Other

842


898






10,617,120


11,015,625





Less: Current portion

(289,676)


(480,182)






$ 10,327,444


$ 10,535,443












5.2

Summary of Cash Flow Statement

Three Months Ended





March 31,





2013


2012





Cash flow provided by (used in):
















Net cash provided by operating activities (GAAP)

$      255,349


167,230





Restructuring, acquisition-related and other costs (c)

56,884


69,842





Payment of accrued legal settlements

2,820


60





Payment of accreted interest on convertible debt

-


56





Tax Benefit from stock options exercised (a)

4,604


593





Working Capital change related to business development activities

19,981


-





Changes in working capital related to restructuring, acquisition-related and other costs(c)

5,750


17,539





Adjusted cash flow from operations (Non-GAAP) (b)

$      345,388


$      255,320



















(a) Includes stock option tax benefit which will reduce taxes in future periods.





(b) See footnote (a) to Table 2a.





(c) Total Restructuring, acquisition-related and other costs cash payments of $62,634 are broken down as follows:










Project Type

Amount Paid















Medicis

32,810







Intellectual property migration

6,536







Other

4,522







Europe (including Nature Produkt & Lek-Am)

4,435







Manufacturing integration (various deals)

3,640







U.S. restructuring

2,767







OraPharma

2,490







Ophthalmology (QLT and Eyetech)

1,992







Swiss Herbal/Afexa

1,948







Systems integration (various deals U.S./Canada)

1,494















Total

$                62,634















Expense Type

Amount Paid















Severance payments

29,265







Integration related consulting, duplicative labor, transition services, and other

26,212







Facility closure costs, other manufacturing integration, and other

3,604







Acquisition-related costs paid to 3rd parties

3,553















Total

$                62,634














 


Valeant Pharmaceuticals International, Inc.




Table 6

Organic Growth - by Segment 





For the Three Months Ended March 31, 2013



(In thousands)























 For the Three Months Ended March 31, 2013 















 Organic growth 










(a)

(b)




 (b) 


 (b) 


 (1) QTD
2013

 (2) Acq impact

 (3) QTD
Same store


 (4) QTD
2012

 (5) Pro Forma Adj

 (6) Pro Forma 2012


 (7) Currency impact Same store

 (8) Currency impact Acq


 (9) Divestitures / Discontinuations (c)


Pro Forma (1)+(7)+(8)+(9) / (6)


Same store (3)+(7) / (4)-(9)


















U.S. Promoted

478.6

217.9

260.7


250.6

233.9

484.5


-

-


4.8


0%


6%

U.S. Neurology & Other (d)

158.4

24.0

134.4


153.5

15.7

169.1


-

-


3.5


-4%


-10%

Canada/Australia    (e) 

119.0

14.7

104.3


121.5

16.9

138.4


1.1

0.1


3.0


-11%


-11%

Developed Markets

755.9

256.6

499.4


525.6

266.4

792.0


1.1

0.1


11.3


-3%


-3%

Emerging Markets - Central/Eastern Europe

178.6

36.0

142.6


134.3

32.1

166.4


(0.3)

0.2


5.9


11%


11%

Emerging Markets - Latin America

81.7

12.0

69.8


70.9

11.6

82.5


2.6

0.5


3.2


7%


7%

Emerging Markets - Southeast Asia/Africa

26.4

-

26.4


21.9

-

21.9


1.7

-


0.0


28%


28%

Emerging Markets

286.8

48.0

238.8


227.1

43.7

270.9


4.1

0.7


9.2


11%


11%

Total product sales

1,042.7

304.5

738.2


752.7

310.2

1,062.9


5.2

0.8


20.5


1%


2%




































Normalized for:       1) Generic impact of Cesamet, BenzaClin and other generics


                                       2) Assets held for sale (various brands in Australia and Canada)




































 For the Three Months Ended March 31, 2013 















 Organic growth 










(a)

(b)




 (b) 


 (b) 


 (1) QTD
2013

 (2) Acq impact

 (3) QTD
Same store


 (4) QTD
2012

 (5) Pro Forma Adj

 (6) Pro Forma 2012


 (7) Currency impact Same store

 (8) Currency impact Acq


 (9) Divestitures / Discontinuations (c)


 Pro Forma (1)+(7)+(8)+(9) / (6)


Same store (3)+(7) / (4)-(9)


















U.S. Promoted (f) (h)

473.9

217.9

256.0


233.8

233.9

467.7


-

-


4.8


2%


12%

U.S. Neurology & Other (d) (i)

158.4

24.0

134.4


153.5

15.7

169.1


-

-


3.5


-4%


-10%

Canada/Australia    (e) (g)

106.4

14.7

91.7


91.6

16.9

108.5


1.1

0.1


3.0


2%


5%

Developed Markets

738.7

256.6

482.1


478.9

266.4

745.3


1.1

0.1


11.3


1%


3%

Emerging Markets - Central/Eastern Europe

178.6

36.0

142.6


134.3

32.1

166.4


(0.3)

0.2


5.9


11%


11%

Emerging Markets - Latin America

81.7

12.0

69.8


70.9

11.6

82.5


2.6

0.5


3.2


7%


7%

Emerging Markets - Southeast Asia/Africa

26.4

-

26.4


21.9

-

21.9


1.7

-


0.0


28%


28%

Emerging Markets

286.8

48.0

238.8


227.1

43.7

270.9


4.1

0.7


9.2


11%


11%

Total product sales (j)

1,025.5

304.5

720.9


706.0

310.2

1,016.2


5.2

0.8


20.5


4%


6%


















(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. 

(b) See footnote (a) to Table 2a.

(c) Includes divestitures, discontinuations and supply interruptions.

(d) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $1.7M Q1'13.

(e) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $1.8M Q1'12 and $2.2M Q1'13.

(f)  Excludes revenue from genericized products of $16.8M Q1'12 and $4.7M Q1'13.

(g) Excludes revenue from genericized products and assets held for sale of $29.9M Q1'12 and $12.6M Q1'13.

(h) Includes impact of $22.5M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 7% for the quarter.

(i)  Includes impact of $1.5M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 3% for the quarter.

(j)  Includes impact of $24.0M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 6% for the quarter.


















 

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

SOURCE Valeant Pharmaceuticals International, Inc.



RELATED LINKS
http://www.valeant.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.